Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma patients not undergoing autologous stem cell transplant: The phase III TOURMALINE-MM4 trial
What is the phase III TOURMALINE-MM1 trial?
Maintenance therapy delays disease progression in newly diagnosed multiple myeloma (NDMM) patients who do not undergo autologous stem cell transplant (ASCT). However, in practice, currently used maintenance therapies may be limited to fixed duration due to toxicity and route of administration; additional options are needed.
The TOURMALINE-MM1 trials uses ixazomib maintenance therapy in non-ASCT NDMM patients.
In this video:
Dr. Meletios A. Dimopoulos (University of Athens — Athens, Greece) explains the methods and results of the phase III TOURMALINE MM-1 study.
Results and conclusions:
Ixazomib maintenance therapy showed a clinically meaningful 34% reduction in the risk of progression or death, with a well-tolerated safety profile. Ixazomib is the first oral proteasome inhibitor (PI) maintenance option for non-ASCT NDMM patients.
Clinical trial information: NCT02312258
MELETIOS A. DIMOPOULOS, MD
Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the University Athens School of Medicine, Athens, Greece. He has been elected Vice Dean of the Medical School for the academic years 2007-2011 and Dean for the academic years 2011-2013. He obtained his medical degree from the University of Athens in 1985, completed a residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada and a fellowship in hematology/oncology at the University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. Dr. Dimopoulos is a member of numerous scientific societies and has authored more than 650 publications (April 2013) in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias and genitourinary and gynecologic cancers.